Effect of montelukast combined with tiotropium bromide in bronchial asthma patients in remission stage

Objective To explore the effects of montelukast combined with tiotropium bromide on the levels of inflammatory mediators, T cell subsets and adhesion factors in induced sputum of patients with bronchial asthma during remission. Methods A total of 96 children patients with bronchial asthma during remission period were selected. According to random number table method, 96 children patients were divided into observation group and control group, with 48 cases in each group. Control group was treated with tiotropium bromide, and observation group was given montelukast combined with tiotropium bromide, and the two groups were continuously treated for 3 months. The levels of lung function indexes and inflammatory factors, T cell subsets and adhesion factors in induced sputum before and after treatment, and adverse reactions during treatment were compared between the two groups. Results After treatment, the forced expiratory volume in 1 second(FEV₁), forced vital capacity(FVC)and percentage of maximum forced respiratory peak flow in predicted value(PEF%)in the observation group were significantly higher than those in the control group(P<0.05); the levels of interleukin-6(IL-6)、interleukin-8(IL-8)and tumor necrosis factor(TNF-α)in the observation group were significantly lower than those in the control group(P<0.05); the Th1,CD8⁺CD28^- and CD4⁺CD25⁺ in induced sputum were significantly higher than those in the control group, while the Th2 and Th17 were significantly lower than those in the control group(P<0.05); the levels of intercellular adhesion molecule-1(ICAM-1), vascular cell adhesion molecule-1(VCAM-1)and CD44 in - induced sputum in the observation group were significantly lower than those in control group(P<0.05). There was no statistically significant difference in the incidence rate of adverse reactions between the two groups(P>0.05). Conclusion Montelukast combined with tiotropium bromide in the treatment of patients with bronchial asthma during remission can effectively recieve local airway inflammation and adhesion, and regulate immune function.